Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $94.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 70.55% to $94.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $551.7 million, a 48.29% decrease, with the full-year FY2025 number at $551.7 million, down 48.29% from a year prior.
  • Change in Acquisitions & Divestments was $94.7 million for Q4 2025 at Intellia Therapeutics, down from $115.9 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $321.6 million in Q4 2024 to a low of $73.3 million in Q2 2021.
  • A 5-year average of $181.9 million and a median of $194.9 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 397.97% in 2021, then plummeted 70.55% in 2025.
  • Intellia Therapeutics' Change in Acquisitions & Divestments stood at $94.6 million in 2021, then skyrocketed by 122.16% to $210.2 million in 2022, then fell by 6.17% to $197.2 million in 2023, then skyrocketed by 63.08% to $321.6 million in 2024, then tumbled by 70.55% to $94.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Change in Acquisitions & Divestments are $94.7 million (Q4 2025), $115.9 million (Q3 2025), and $162.7 million (Q2 2025).